Tony Kingsley

Tony Kingsley joined The Medicines Company (MDCO) in May 2016 as President and Chief Operating Officer. Before joining MDCO, Tony was Executive Vice President, Global Commercial Operations at Biogen, where he oversaw the launch of multiple new therapies, including TECFIDERA®, the most-prescribed oral treatment for multiple sclerosis today. Prior to Biogen, he served as Senior Vice President and General Manager of the Gynecological Surgical Products business at Hologic, Inc., and as Division President, Diagnostic Products, at Cytyc Corporation.

Bill O'Connor

Bill O'Connor has been a Special Advisor to the Chief Executive Officer of The Medicines Company (MDCO) since March 2018. Previously, Bill served as MDCO’s Chief Financial Officer from 2016 to 2018 and Chief Accounting Officer from 2008 to 2016. Before joining MDCO, Bill was the Vice President of Finance for Eyetech Pharmaceuticals, Inc. from 2000 to 2006 and worked in various finance roles at Trophix Pharmaceuticals, Inc. from 1996 to 2000. Prior to 1996, Bill worked in the public accounting sector for approximately 15 years.

Chris Cox

Chris Cox joined The Medicines Company (MDCO) in February 2016 as Executive Vice President and Chief Corporate Development Officer. Prior to joining MDCO, Chris spent over 20 years as a corporate attorney, most recently at Cadwalader, Wickersham & Taft LLP, where he was Co-Chair of the Firm’s Corporate Group and a member of its Management Committee. He joined Cadwalader in January 2012. Previously, he was a Partner at Cahill Gordon & Reindel LLP.

Alexander J. Denner, Ph.D

Alexander J. Denner, Ph.D., has been a director since February 2016 and chairman since June 2018. Dr. Denner is the founding partner and the chief investment officer of Sarissa Capital Management LP, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to better enhance shareholder value. From 2006 to 2011, Dr. Denner served as a senior managing director at Icahn Capital, an entity through which Carl Icahn conducts his investment activities.


Subscribe to The Medicines Company RSS